Efficacy News and Research

RSS

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Edoxaban in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting.

4 Sep 2019

CRISPR-Cas9 successfully reverses type 2 diabetes in mice

Researchers have used CRISPR-Cas9 to treat obesity and type 2 diabetes in mice, a development that could eventually benefit humans.

3 Sep 2019

Study highlights the need to better understand immunity against mumps virus

Immunity against mumps virus appears insufficient in a fraction of college-aged people who were vaccinated in childhood, research from Emory Vaccine Center and the Centers for Disease Control and Prevention indicates.

3 Sep 2019

Beta-blockers reduce mortality in patients with heart failure and moderate kidney dysfunction

Beta-blockers remain effective for preventing death in heart failure with reduced ejection fraction (HFrEF) and sinus rhythm, even in patients with moderate or moderately-severe kidney dysfunction, according to late breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology.

3 Sep 2019

Diet can alter efficacy of type-2 diabetes drug via its action on gut bacteria, study shows

Research published in Cell on 29th August by the groups of Filipe Cabreiro from the MRC London Institute of Medical Sciences and Imperial College and Christoph Kaleta from Kiel University in Germany has demonstrated that diet can alter the effectiveness of a type-2 diabetes drug via its action on gut bacteria.

30 Aug 2019

Cracking the code of a recurrent brain cancer

One of the most common brain cancers in children, Sonic Hedgehog (SHH) medulloblastoma, also is one of the more survivable for most kids. Unfortunately, for a subset of patients the cancer resists treatment and relapses with a vengeance to then turn deadly.

30 Aug 2019

'Lab on a chip' technology may help find new treatments for NAFLD

Non-alcoholic fatty liver disease--the accumulation of liver fat in people who drink little or no alcohol--is increasingly common around the world, and in the United States, it affects between 30 and 40 percent of adults.

29 Aug 2019

Graphene-lined fabric could slow the spread of malaria

Lining clothes with graphene could prevent the spread of malaria as mosquitoes are not able to pick up on chemical signals that encourage them to bite.

29 Aug 2019

DNA vaccine for tick-borne disease ‘SFTS’ confers protection against lethal infection in ferrets

A KAIST research team reported the development of a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) which completely protects against lethal infection in ferrets.

29 Aug 2019

Investigational drug reduces stuttering symptoms in open-label pilot study

A team led by a psychiatrist at the University of California, Riverside, has tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms from the start of therapy after eight weeks of dosing.

28 Aug 2019

Potential drug could revolutionize the treatment of neurological conditions

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may prevent neuronal death through glucose metabolism modification in stressed neurons.

28 Aug 2019

Researchers find a weak spot in cancer cells

Cancer cells form tumors. This statement, simple as it seems, hides a complex failure of normal immune responses that should eliminate tumor cells from the body before they ever form viable cancer masses.

28 Aug 2019

Promising vaccine may protect against the Klebsiella superbug

A powerful superbug, a hypervirulent form of the bacteria Klebsiella pneumoniae, is a very difficult to curb infection. It causes a variety of infections including rare but life-threatening liver, respiratory tract, bloodstream and other infections.

28 Aug 2019

New drug combination shows promise for treating non-small cell lung cancer patients

Patients with non-small cell lung cancer now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors.

27 Aug 2019

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”

27 Aug 2019

Traumatic brain injuries could be healed using peptide hydrogels

Traumatic brain injury (TBI) –– defined as a bump, blow or jolt to the head that disrupts normal brain function –– sent 2.5 million people in the U.S. to the emergency room in 2014, according to statistics from the U.S. Centers for Disease Control and Prevention.

27 Aug 2019

Genetically altering protein in colon cancer cells may enhance efficacy of chemotherapy

Colorectal cancer outcomes may improve by genetically altering an immune-regulatory protein in cancer cells, making the cells more vulnerable to chemotherapy. That's according to new Mayo Clinic research.

27 Aug 2019

Multi-site study of noninvasive brain stimulation to improve upper limb function after spinal cord injury

Kessler Foundation is one of three sites participating in a study of noninvasive brain stimulation to improve upper limb function funded by the U.S. Department of Defense Congressionally Directed Medical Research Programs titled, "Improving Spinal Cord Injury Rehabilitation Interventions by Retraining the Brain." Ela Plow, PhD, is principal investigator for the Cleveland Clinic; Svetlana Pundik, PhD, is principal investigator for the Louis B. Stokes VA Cleveland Medical Center; and Gail Forrest, PhD, is principal investigator for the Foundation, which received a sub-award of $778,000. Dr. Forrest is director of the new Center for Spinal Stimulation at Kessler Foundation.

27 Aug 2019

Studying human behavior might help curb mosquito-borne illness

Control and prevention of Aedes-transmitted viruses, such as dengue, chikungunya, or Zika relies heavily on vector control approaches. Given the effort and cost involved in implementation of vector control, targeting of control measures is highly desirable. However, it is unclear to what extent the effectiveness of highly focal and reactive control measures depends on the commuting and movement patterns of humans.

27 Aug 2019